Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 9, 2009, Pages 848-857

  Khalili, Hossein ^a   Dashti Khavidaki, Simin ^a   Mohraz, Minoo ^b   Etghani, Atefeh ^a   Almasi, Farahnaz ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug reaction; Antiretroviral drugs; HIV patients

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; STAVUDINE;

ABDOMINAL PAIN; ADULT; AGITATION; ANEMIA; ANOREXIA; ARTICLE; CHOLESTASIS; CLINICAL EXAMINATION; COHORT ANALYSIS; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLACTATEMIA; IRAN; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; LIVER TOXICITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIXED INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; URTICARIA; VERTIGO; VOMITING; WEAKNESS;

ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; IRAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 70450214715     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1793     Document Type: Article

References (66)

1. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499-507.
2. Manzardo C, Zaccarelli M, Aguero F, et al. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007; 46 (Suppl 1): S9-S18. (Pubitemid 47312321)
3. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse drug events associated with potent antiretroviral treatment: Swiss HIV Cohort study. Lancet 2001; 358(9290): 1322-1327. (Pubitemid 33016496)
4. Rudorf DC, Krikorian SA. Adverse effects associated with antiretroviral therapy and potential management strategies. J Pharm Pract 2005; 18(4): 258-277. (Pubitemid 41003820)
5. Ward HA, Russo GG, Shrum J. Cutaneous manifestations of antiretroviral therapy. J Am Acad Dermatol 2002; 46: 284-293.
6. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902.
7. Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170(2): 229-238. (Pubitemid 38134804)
8. Durrieu G, Lacroix I, Olivier P, et al. Réseau français des centres régionaux de pharmacovigilance (CRPVs). Drug-related neuropathies: analysis of the French Adverse Drug Reaction Database 1995-2005. Presse Med 2008; 37(6 Pt 1): 935-942.
9. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44 (suppl 1): S132-S139. (Pubitemid 43053889)
10. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32(3): 492-497.
11. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23(3): 236-245.
12. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001; 12(9): 555-562.
13. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131(2): 81-87.
14. World Health Organization. Uppsala Monitoring Center, Safety monitoring of medicinal products, guidelines for setting up and running pharmacovigilance center, Geneva, 1996.
15. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
16. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229-2232.
17. Benichou C, Danan G. A new method for drug causality assessment: RUCAM. In Adverse Drug Reactions. A Practical Guide to Diagnosis an Management, Benichou C (ed.). John Wiley & Sons: New York, 1994; 277-284.
18. Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17(6): 374-389.
19. Mildvan D, Creagh T, Leitz G. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007; 23(2): 343-355. (Pubitemid 46333383)
20. van der Klauw MM, Goudsmit R, Halie MR, et al. A population-based case cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159(4): 369-374. (Pubitemid 29091625)
21. Kaplowitz N. Drug-induced liver injury. Clin Infec Dis 2004; 38 (suppl 2): S44-S48.
22. WHO. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology. WHO Collaborating Center for International Drug Monitoring: Uppsala, 1992.
23. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-239. (Pubitemid 38924592)
24. Imhof A, Ledergerber B, Gunthard HF, et al. Risk factors for and outcomes of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infect Dis 2005; 41: 721-728.
25. Boubaker K, Flepp M, Surde P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33(11): 1931-1937. (Pubitemid 33105136)
26. Chariot P, Gherardi R. Myopathy and HIV infection. Curr Opin Rheutiol 1995; 7(6): 497-502.
27. Rudorf DC. Adverse effects associated with antiretroviral therapy and potential management strategies. J pharm pract 2005; 18(4): 258-277. (Pubitemid 41003820)
28. Belpeiro PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004; 116(7A): 27S-43S.
29. Sullivan PS, Hanson DL, Chun SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91(1): 301-308.
30. Koduri PR, Parekh S. Zidovudine-related anemia with reticulocytosis. Ann Hematol 2003; 82(3): 184-185.
31. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317(4): 192-197. (Pubitemid 17103099)
32. Guitton E, Montastruc JL, Lapeyre-Mestre M. The French Network of Pharmacovigilance Centres. Influence of HCVor HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 2006; 62(3): 243-249.
33. Moore RD, Fortgang I, Keruly J, et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101(1): 34-40. (Pubitemid 26285938)
34. SUSTIVATM (efavirenz) capsules, US Prescribing Information. Du Pont Pharmaceuticals Company: Wilmington, DE, 2000.
35. Sharma A, Vora R, Modi M, Sharma A, et al. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008; 74(3): 234-237.
36. Fagot JP, Mockenhaupt M, Bouwes-Bavnick JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15(14): 1843-1848. (Pubitemid 32939246)
37. Gangar M, Arias G, O'Brien JG, et al. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 2001; 34: 839-842. (Pubitemid 30471262)
38. Schieferstein C, Buhk T. Management von Nebenwirkungen. In HIV.- NET 2005, Hoffmann C, Rockstroh JK, Kamps SK (eds). Steinhäuser Verlag: Wuppertal-Beyenburg, 2005; 267-285.
39. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83(1): 1-9. (Pubitemid 36223045)
40. Mazhude C, Jones S, Murad S, et al. Female sex but not ethnicity is a strong predictor of nonnucleoside reverse transcriptase inhibitorinduced rash. AIDS 2002; 16(11): 1566-1568. (Pubitemid 34804228)
41. Knobel H, Guelar A, Montero M, et al. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4cell count. HIV Med 2008; 9(1): 14-18.
42. Derisi M, Ballard C, Abulhosn K, et al. Abstract 61: Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash. 7th Conference on retroviruses and opportunistic infections, San Francisco, CA; January 30-February 2, 2000.
43. Granel F, Truchetet F, Grandidier M. Diffuse pigmentation (nail, mouth and skin) associated with HIV infection. Ann Dermatol Venereol 1997; 124: 460-462.
44. Greenberg RG, Berger TG. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol 1990; 22: 327-330.
45. Selik RM, Byers RH, Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999 . J Acquir Immune Defic Syndr 2002; 29(4): 378-387.
46. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44(suppl 1): S132-S139. (Pubitemid 43053889)
47. Reisler R, Liou S, Servoss JC, et al., Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials [abstract 43]. ACTG Liver Diseases Focus Group. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Jul 8-11, 2001.
48. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003; 5(1): 36-43.
49. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283(1): 74-80. (Pubitemid 30038386)
50. Bissuel F, Bruneel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994; 235(4): 367-371. (Pubitemid 24210849)
51. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357(9256): 592-598. (Pubitemid 32179612)
52. den Brinker M,Wit FW,Wetheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14(18): 2895-2902. (Pubitemid 32042753)
53. Nunez M, Lana R, Mendoza J, et al. Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Immune Def Syndr 2001; 27: 426-431.
54. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIVexposures-worldwide, 1997-2000. MMWR Morbid Mortal Wkly Rep 2001; 49(51-52): 1153-1156.
55. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al. A cohort study of nevirapin tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis 2002; 35(10): 1231-1237.
56. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13(13): 1359-1367. (Pubitemid 30015713)
57. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13(7): 805-810. (Pubitemid 29224582)
58. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001; 12(9): 555-564.
59. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS 2000; 14(3): 25-32. (Pubitemid 30132938)
60. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40(2): 121-131. (Pubitemid 41395709)
61. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: 51-58. (Pubitemid 28190689)
62. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31(1): 162-166. (Pubitemid 32268957)
63. Harris M, Tesiorowski A, Chan K, et al. Lactic acidosis complicating antiretroviral therapy: frequency and correlates. Antivir Ther 2000; 5 (Suppl 2): 31.
64. Tesiorowski AM, Harris M, Chan KJ, et al. Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31(2): 250-251. (Pubitemid 35190581)
65. Rao TK. Acute renal failure in human immunodeficiency virus infection. Semin Nephrol 1998; 18(4): 378-395. (Pubitemid 28340462)
66. Rho M, perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2007; 2(2): 147-154.